荨麻疹临床试验招募信息（全球在招）
这里汇总了全球正在招募患者的 荨麻疹（国际通用名 chronic urticaria）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。
正在招募的荨麻疹新药试验
Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)
I 期招募中加拿大NCT07247266Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
I 期招募中美国NCT06974877ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar
不适用招募中法国NCT07425639Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.
III 期招募中中国NCT07402213Analysis of the Role of IgE Proteoforms in Health and Disease
不适用招募中BelgiumNCT07328178Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex, IHC (Histoglob) in Chronic Urticaria
不适用招募中IndiaNCT07680413Remibrutinib in Real-world Clinical Practice - a US Sub-study
不适用招募中美国NCT07358780Deployment o the Multidisciplinary Prospective Cohort Imminent
不适用招募中法国NCT04334031Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)
不适用招募中美国NCT02974595Deep Phenotyping of CIndU
不适用招募中NetherlandsNCT07359430A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
I 期招募中德国NCT07181369A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
III 期招募中美国NCT06868212
荨麻疹试验不在中国大陆，还能参加吗？
可以尝试四条现实路径：查找国内同类试验、申请同情用药与扩展准入、赴境外研究中心入组、直接写信给申办方申请在华开展。本站提供中英文对照的咨询信模板，患者和家属填写基本情况即可生成。